How I treat <scp>triple‐class</scp> refractory multiple myeloma-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

How I treat triple‐class refractory multiple myeloma

Published:2022-04-03 Issue:2 Volume:198 Page:244-256
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Costa Luciano J.¹^ORCID,Hungria Vania²^ORCID,Mohty Mohamad³^ORCID,Mateos Maria‐Victoria⁴^ORCID

Affiliation:

1. Division of Hematology and Oncology Department of Medicine, University of Alabama at Birmingham Birmingham Alabama USA

2. Clinica São Germano São Paulo Brazil

3. Sorbonne University Clinical Hematology and Cellular Therapy Department, Saint Antoine Hospital, INSERM UMRs U938 Paris France

4. Department of Haematology University Hospital of Salamanca Salamanca Spain

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjh.18185

Reference92 articles.

1. Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study

2. Mortality trends in multiple myeloma after the introduction of novel therapies in the United States

3. Recent trends in multiple myeloma incidence and survival by age, race, and ethnicity in the United States

4. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study

5. Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Phase II trial of elotuzumab with pomalidomide and dexamethasone for daratumumab-refractory multiple myeloma;Blood Cancer Journal;2024-09-05

2. A phase Ib trial of isatuximab, bendamustine, and prednisone in relapsed/refractory multiple myeloma;Annals of Hematology;2024-09-04

3. The first case of multiple myeloma treated with ASCT followed by Anti-BCMA CAR-T cells using retrovirus vector: A case report;Heliyon;2024-09

4. High CD38 expression defines a mitochondrial function adapted CD8 + T cell subset with implications for lung cancer immunotherapy;2024-08-28

5. Intensive salvage chemotherapy with VDTPACE or mCBAD followed by hematopoietic stem‐cell support for refractory/relapsed multiple myeloma;European Journal of Haematology;2024-06-18

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3